Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 62

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Rhinitis allergic+1

Not yet recruiting

Evaluation of Alutard SQ dog allergen immunotherapy in patients with allergic rhinitis due to dog allergy - A one-year study in Swedish practice

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Desloratadine
  • Sponsor:Karolinska Institutet

Myasthenia gravis

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Type 1 diabetes mellitus

Not yet recruiting

Study on Verapamil and Exenatide for Adults with Type 1 Diabetes to Measure Changes in Beta Cell Mass

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Exenatide
  • Sponsor:Stichting Radboud University Medical Center

Systemic lupus erythematosus

Not yet recruiting

Study on the Effectiveness of Telitacicept for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Remegen Co. Ltd.

Haemophagocytic lymphohistiocytosis

Not yet recruiting

Study on Etoposide for Patients with Severe Hemophagocytic Lymphohistiocytosis in Intensive Care

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Assistance Publique Hopitaux De Paris

Endocrine ophthalmopathy

Not yet recruiting

Study on the Effects of VRDN-003 for Patients with Active Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Cerebral amyloid angiopathy+2

Not yet recruiting

Study of [18F]MC225 to Assess P-glycoprotein Function in Patients with Alzheimer's, Mild Cognitive Impairment, and Parkinson's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Mc225
  • Sponsor:Universitair Medisch Centrum Groningen

Still's disease+1

Not yet recruiting

Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Universitair Medisch Centrum Utrecht

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not yet recruiting

Study of KYV-101, Fludarabine Phosphate, and Cyclophosphamide Monohydrate for Patients with Treatment-Resistant ANCA Vasculitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Kyv-101
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Henoch-Schonlein purpura

Not yet recruiting

Study of rituximab and glucocorticoids versus placebo and glucocorticoids in adults with newly diagnosed or relapsing IgA vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Hospital Foch

HIV infection

Not yet recruiting

Study on Doravirine and Raltegravir for Maintaining Viral Control in HIV Patients with Low Viral Load

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida

Eosinophilic oesophagitis

Not yet recruiting

Study on the Use of Viscous Budesonide for Children with Eosinophilic Esophagitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:University Hospital Consorziale Policlinico

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.